The White House has signed an executive order instructing US health and justice agencies to accelerate the path to market and limited pre‑approval access for psychedelic therapies, explicitly naming ibogaine alongside other candidates being studied for serious mental illness.

The order tells the Food and Drug Administration to prioritise psychedelic drugs that already have Breakthrough Therapy status, including by issuing “Commissioner’s National Priority Vouchers.” It directs the FDA and the Drug Enforcement Administration to create a pathway under the federal Right to Try law so eligible patients can access psychedelic drugs — including ibogaine compounds — before full approval, and to provide any necessary Schedule I handling authorisations for treating clinicians and researchers.

The Department of Health and Human Services is instructed, via the Advanced Research Projects Agency for Health, to allocate at least US$50 million from existing funds to partner with states that have, or are developing, programmes to advance psychedelic treatments for serious mental illnesses. The order also requires HHS and the FDA to work with the Department of Veterans Affairs and, where appropriate, the private sector to increase clinical trial participation, share data and generate real‑world evidence, with memoranda to ensure relevant study data flows to the FDA.

Separately, the Attorney General must initiate and complete rescheduling reviews, in consultation with HHS, for any product containing a Schedule I substance that successfully completes Phase 3 trials for a serious mental health disorder, so rescheduling can proceed “as quickly as practicable” if the product is ultimately approved.

The order frames the move against rising suicide rates and the burden of serious mental illness in the US, noting long‑running concerns for veterans. It argues that some patients do not fully respond to standard therapies and says psychedelic drugs “show potential” in clinical studies. While naming ibogaine — a compound that has drawn interest for addiction treatment but has known cardiac risks — the order does not approve any specific product, create new legal rights, or commit new funding beyond the $50m reallocated to state collaborations.

What to watch:

• Which psychedelic candidates receive FDA priority vouchers and how quickly DEA handling authorisations are issued for clinicians and researchers.
• How the VA expands participation in clinical trials and data sharing with the FDA.
• Which states partner with HHS for the $50m programme and what models they adopt.
• Any rescheduling moves following positive Phase 3 results for specific products.

Why it matters here: US decisions often shape global research investment and regulatory thinking. Faster federal pathways, VA‑backed data, and any rescheduling decisions in the US are likely to influence how other regulators assess safety, efficacy and access for psychedelic‑assisted treatments, including for veterans and patients with treatment‑resistant conditions.